Prognostic Impact of Tumor Growth Velocity in Head and Neck Squamous Cell Carcinoma Treated by Radio(Chemo)Therapy

Launched by CENTRE HOSPITALIER UNIVERSITAIRE UCLOUVAIN NAMUR · Dec 9, 2016

Keywords

ClinConnect Summary

This clinical trial is investigating how the speed at which tumors grow affects the survival of patients with head and neck squamous cell carcinoma (HNSCC) who are receiving radiation or chemotherapy. Researchers want to understand if measuring the growth of the tumor and related lymph nodes can help predict how long patients might live without the disease coming back. They will use CT scans to look at tumor size and growth, and will also examine tissue samples to see how quickly the tumor cells are multiplying and if they are related to a virus known as HPV.

To be part of this study, patients must have a confirmed diagnosis of HNSCC and be eligible for radiation treatment. They cannot have cancer that has spread to other parts of the body or have undergone surgery as their main treatment. The trial is not yet recruiting participants, and the researchers hope to gather valuable information over the next five years that could help improve future treatments for head and neck cancers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • clinical and anatomopathological diagnosis of a head and neck squamous cell carcinoma (T1 to T4) (oral cavity, oropharynx, larynx, hypopharynx)
• • multidisciplinary decision for radiotherapy or concomitant radiochemotherapy eligibility
• Exclusion Criteria:
• • metastatic disease
• • primary surgical management
• • contraindications to iodine contrast injection: anaphylaxis and renal insufficiency
• • tumor not visible on CT